Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.6.5 has been added to the page as a new version identifier. The Plain Language Summary and Revision: v3.6.4 have been removed, indicating a small administrative update to the study documentation.SummaryDifference0.1%

- Check11 days agoChange DetectedThe page shows updated and removed date entries (e.g., 2026-07-30, 2026-08-21, 2026-07-28, 2026-07) indicating maintenance timestamps rather than changes to the study content.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision label changed from v3.6.3 to v3.6.4 in the history, signaling a new build or update of the page. This reflects deployment/maintenance activity rather than changes to the study details.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.6.0 to v3.6.3 on the study entry, representing a minor metadata update to the ClinicalTrials.gov record. It does not alter study details, eligibility, locations, or results.SummaryDifference0.0%

- Check62 days agoChange DetectedThe substudy page now shows that recruitment is closed for new participants and adds user-facing sections to help visitors read the study record and find information on joining; a minor heading reform for the Intervention/Treatment section and a page revision note (v3.6.0) are also present.SummaryDifference0.3%

- Check69 days agoChange DetectedThe page's revision tag was updated to v3.5.5 and the previous v3.5.4 tag was removed, indicating a new release of the page content. This appears to be an administrative/versioning update rather than a substantive change to study information.SummaryDifference0.0%

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.